These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 19464057)

  • 1. A high-throughput candidate gene mutation screen in lymphoproliferative and myeloproliferative neoplasias.
    Kreil S; Hochhaus A; Cross NC; Chase A
    Leuk Res; 2009 Sep; 33(9):e168-9. PubMed ID: 19464057
    [No Abstract]   [Full Text] [Related]  

  • 2. [New insight into myelodysplastic syndromes and related myeloid disorders].
    Ogawa S
    Rinsho Ketsueki; 2013 Jun; 54(6):533-7. PubMed ID: 23823091
    [No Abstract]   [Full Text] [Related]  

  • 3. New molecular insights in myelodysplastic and myeloproliferative disorders.
    Emanuel PD
    Clin Adv Hematol Oncol; 2005 Jun; 3(6):459-60. PubMed ID: 16167021
    [No Abstract]   [Full Text] [Related]  

  • 4. Mutant molecules of interest in myeloproliferative neoplasms: introduction.
    Tefferi A
    Acta Haematol; 2008; 119(4):192-3. PubMed ID: 18566535
    [No Abstract]   [Full Text] [Related]  

  • 5. Acquired mutation the key to MPDs.
    Everington T
    Practitioner; 2007 Jan; 251(1690):30, 32, 35. PubMed ID: 17290854
    [No Abstract]   [Full Text] [Related]  

  • 6. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders.
    Musolino C; Allegra A; Penna G; Centorrino R; Cuzzola M; D'Angelo A; Iacopino P; Alonci A
    Acta Haematol; 2009; 122(1):46-9. PubMed ID: 19816006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Genomic abnormalities and pathophysiology in myelodysplastic syndrome].
    Chiba S
    Rinsho Ketsueki; 2013 Oct; 54(10):1687-96. PubMed ID: 24064818
    [No Abstract]   [Full Text] [Related]  

  • 8. Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders.
    Cerri M; Capello D; Muti G; Rambaldi A; Paulli M; Gloghini A; Berra E; Deambrogi C; Rossi D; Franceschetti S; Conconi A; Morra E; Pasqualucci L; Carbone A; Gaidano G
    Br J Haematol; 2004 Nov; 127(3):362-4. PubMed ID: 15491294
    [No Abstract]   [Full Text] [Related]  

  • 9. Mutation analysis of the HAX1 gene in childhood myelodysplastic syndrome.
    Steinemann D; Praulich I; Otto N; Göhring G; Niemeyer CM; Schlegelberger B
    Br J Haematol; 2009 May; 145(4):533-4. PubMed ID: 19298594
    [No Abstract]   [Full Text] [Related]  

  • 10. Alport syndrome. Molecular genetic aspects.
    Hertz JM
    Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.
    Eisenmann KM; Dykema KJ; Matheson SF; Kent NF; DeWard AD; West RA; Tibes R; Furge KA; Alberts AS
    Oncogene; 2009 Oct; 28(39):3429-41. PubMed ID: 19597464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [FOXP1 in B-lymphoproliferative diseases].
    Mara D
    Lijec Vjesn; 2007 May; 129 Suppl 3():43. PubMed ID: 18959064
    [No Abstract]   [Full Text] [Related]  

  • 13. Myelodysplastic/Myeloproliferative disorder with severe leukocytosis: a case report.
    Oluwole O; Awujo A; Ivonye C; Sanders L
    Am J Clin Oncol; 2009 Jun; 32(3):326-7. PubMed ID: 19887993
    [No Abstract]   [Full Text] [Related]  

  • 14. Lymphoproliferative disorders.
    Young GA
    Pathology; 2005 Dec; 37(6):407-8. PubMed ID: 16373223
    [No Abstract]   [Full Text] [Related]  

  • 15. Good and bad IRF-1: role in tumor suppression versus autoimmune disease.
    Liebermann DA; Hoffman B
    Leuk Res; 2009 Oct; 33(10):1301-2. PubMed ID: 19439353
    [No Abstract]   [Full Text] [Related]  

  • 16. [Myelodysplastic syndromes].
    Matsuda A
    Rinsho Ketsueki; 2009 Mar; 50(3):147-53. PubMed ID: 19352080
    [No Abstract]   [Full Text] [Related]  

  • 17. Isolated deletion of 6q in a patient with myelodysplastic syndrome.
    Gozzetti A; Crupi R; Defina M; Bocchia M; Raspadori D; Lauria F
    Cancer Genet Cytogenet; 2009 Jul; 192(1):51. PubMed ID: 19480939
    [No Abstract]   [Full Text] [Related]  

  • 18. The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes.
    Bacher U; Haferlach T; Kern W; Weiss T; Schnittger S; Haferlach C
    Cancer; 2009 Oct; 115(19):4524-32. PubMed ID: 19569249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical characteristics and LGI1 gene mutation analysis on an autosomal dominant lateral temporal lobe epilepsy].
    Xi ZQ; Wang XF; Lü Y; Wang L; Xiao F; Guan LF
    Zhonghua Yi Xue Za Zhi; 2009 Jan; 89(3):195-7. PubMed ID: 19537038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular diagnosis of myeloproliferative neoplasms.
    Patnaik MM; Tefferi A
    Expert Rev Mol Diagn; 2009 Jul; 9(5):481-92. PubMed ID: 19580432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.